Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention

Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced its participation in the BIO International Convention (BIO 2026), held in San Diego, California, from June 22 to June 25, 2026. Having participated in the BIO International Convention for over a decade without missing a single year, Jyong Biotech once again exhibited at the Taiwan Pavilion. The Company conducted in-depth discussions with global pharmaceutical companies, investment institutions, and industry partners and had the opportunity to present the Company and its assets to them.

During the convention, Jyong Biotech presented its botanical new drug candidate, Botreso ® (API-1), to international pharmaceutical companies as the Company continues advancing global licensing discussions. Targeting benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), the Company has conducted four Phase III clinical trials for Botreso ® across the United States and Taiwan. The Company believes the drug candidate offers a potentially attractive solution for long-term treatment needs, backed by its proven safety, tolerability, and clinical profile.

Driven by an aging global population and rising obesity rates, the BPH and LUTS market continues to expand, with the number of BPH patients projected to grow by 35% to 40% between 2021 and 2035 according to the Global Burden of Disease (GBD 2021) study and BMC Urology. To capitalize on this, Jyong Biotech is accelerating its New Drug Application (NDA) preparations and global licensing plans. Supported by in...